Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: An AGEO prospective multicentre cohort

British Journal of Cancer

Volumn 113, Issue 7, 2015, Pages 989-995

  Portal, Alix ^a   Pernot, Simon ^a   Tougeron, David ^b   Arbaud, Claire ^c   Bidault, Anne Thirot ^d   De La Fouchardière, Christelle ^e   Hammel, Pascal ^f   Lecomte, Thierry ^g   Dréanic, Johann ^h   Coriat, Romain ^h   Bachet, Jean Baptiste ⁱ   Dubreuil, Olivier ⁱ   Marthey, Lysiane ^j   Dahan, Laetitia ^k   Tchoundjeu, Belinda ^l   Locher, Christophe ^m   Lepère, Céline ^a   Bonnetain, Franck ^c   Taieb, Julien ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITÉ LYON 1   (France)

^f BEAUJON HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

^h Sorbonne University ^*  (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j HÔPITAL ANTOINE BÉCLÈRE   (France)

^k TIMONE HOSPITAL   (France)

^l CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^m Emergency Department Smur 77   (France)

more..

Author keywords

metastatic pancreatic cancer; Nab paclitaxel plus gemcitabine; second line chemotherapy; Folfirinox

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER CONTROL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FRANCE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPESTHESIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PARESTHESIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSORY NEUROPATHY; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84942988759     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.328     Document Type: Article

References (26)

1. Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M, Culine S (2011) 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 80: 301-306
2. Bachet J-B, Mitry E, Lièvre A, Lepère C, Vaillant J-N, Declety G, Parlier H, Emile J-F, Julié C, Rougier P (2009) Second-And third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients. Gastroenterol Clin Biol 33: 1036-1044
3. Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L (2014) Guidelines for time-To-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-To-event End-points in CANcer trials). Eur J Cancer 50: 2983-2993
4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet J-B, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. Groupe Tumeurs Digestives of UnicancerPRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825
5. Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul J-L, Cattan S, Phelip J-M, Hammel P, Chauffert B, Michel P, Legoux J-L, Rougier P, Bedenne L, Seitz J-F. Fédération Francophone de Cancérologie Digestive (2010) Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 59: 1527-1534
6. Gill S, Ko Y-J, Cripps C, Beaudoin A, Dhesy-Thind B, Zulfiqar M, Zalewski P, Do T, Cano P, Yin Han Lam W, Dowden S, Grassin H, Stewart J, Moore M (2014) PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). J Clin Oncol 32: 5s (suppl; abstr 4022)
7. Giordano G, Miella M, Melisi D, Zaniboni A, Zagonel V, Caponi S, Giommoni E, Santoni M, Vaccaro V, Bertocchi P, Bergamo F, Molinara E, Musettini G, Lucchini E, Febbraro A (2014) Nab-Paclitaxel and Gemcitabine in pretreated advanced pancreatic cancer patients: a multicentre retrospective analysis. Ann Oncol 25(Suppl 4): iv210-iv253
8. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362: 1605-1617
9. Hosein PJ, de Lima Lopes G, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM (2013) A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 36: 151-156
10. Lee MG, Lee SH, Lee SJ, Lee YS, Hwang J-H, Ryu JK, Kim Y-T, Kim DU, Woo SM (2013) 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Chemotherapy 59: 273-279
11. Maréchal R, Bachet J-B, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera E-L, Closset J, Salmon I, Devière J, Emile J-F, Van Laethem J-L (2012) Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143: 664-674.e1-e6
12. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dörken B, Pelzer U (2014) Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 32: 2423-2429
13. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47: 1676-1681
14. Peters GJ, Avan A, Ruiz MG, Orsini V, Avan A, Giovannetti E, Smit EF (2014) Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. Anticancer Res 34: 435-442
15. Portal A, Pernot S, Siauve N, Landi B, Lepère C, Colussi O, Rougier P, Zaanan A, Verrière B, Taieb J (2014) Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. Clin Res Hepatol Gastroenterol 38: e23-e26
16. Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF (2013) Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 24: 1972-1979
17. Safran H, Perez K, Charpentier K, Austin TC, Mantripragada K, Bishop K, Lombardo A, Houlihan L, Mitchell K, Rosati K, Martel D, Shaw L (2014) Nab-paclitaxel combined with Folfox for advanced pancreatic cancer: a phase I study. J Clin Oncol 32: 5s (suppl; abstr 4123)
18. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE Working Group (2009) EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45: 931-991
19. Scripture CD, Figg WD, Sparreboom A (2006) Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol 4: 165-172
20. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29
21. Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-LimaCM (2014) A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol 73: 839-845
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
23. Von Hoff D, Li C-P, Wang-Gillam A, Bodoky G, Dean A, Jameson G, Macarulla T, Lee K-H, Cunningham D, Blanc J-F, Hubner R, Chiu C-F, Schwartsmann G, Siveke J, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Chen L-T (2014) NAPOLI-1: randomized phase 3 study of MM-398 (NAL-IRI), with or without 5-Fluorouracil and leucovorin, versus 5-Fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy. Ann Oncol 25(Suppl 2): ii105-ii106
24. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703
25. Yoo C, Hwang JY, Kim J-E, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim M-H, Han DJ, Kim SC, Lee J-L (2009) A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 101: 1658-1663
26. Zaanan A, Trouilloud I, Markoutsaki T, Gauthier M, Dupont-Gossart A-C, Lecomte T, Aparicio T, Artru P, Thirot-Bidault A, Joubert F, Fanica D, Taieb J (2014) FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer 14: 441